Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800437 | 1.00 | TDP1 (0.57) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL282513 | 0.87 | HTT (0.58) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14451769 | 0.86 | ALDH1A1 (0.47) | TDP1HTTALDH1A1LMNAPOLB | |
| SCHEMBL2434154 | 0.85 | SMN1; SMN2 (0.62) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23833731 | 0.84 | TDP1 (0.57) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5188245 | 0.84 | TDP1 (0.61) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11240386 | 0.84 | TDP1 (0.57) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10786166 | 0.83 | MAPT (0.47) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29451712 | 0.81 | ALDH1A1 (0.66) | TDP1HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23833770 | 0.80 | AKR1C3 (0.41) | TDP1HTTALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086794-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-20250145578-A1 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-05-08 | — | — | US | disclosed |
| CN-118146651-A | Modified carbon black used in black photoresist ink, preparation method and application | 沈阳化工研究院有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023158866-A2 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20230218632-A1 | CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4121072-A1 | CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | Amathus Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121029-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | Amathus Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3256116-B1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022032144-A1 | SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-5359132-A | Process for the preparation of sodium salts of aromatic sulphinic acids containing nitro groups | BAYER AKTIENGESELLSCHAFT (DE) | 1994-10-25 | — | — | US | disclosed |
| EP-0081425-B1 | PHARMACEUTICAL COMPOSITIONS HAVING NORMOLIPEMIC PROPERTIES AND CONTAINING COMPOUNDS OF THE N-SUBSTITUTED BENZENESULFONAMIDE TYPE | CHOAY S.A. (FR) | 1985-09-18 | — | — | EP | disclosed |
| EP-0088849-A1 | Levorotatory compounds of N-substituted benzenesulphone amides, process for their preparation and pharmaceutical compositions containing them | CHOAY S.A. (FR) | 1983-09-21 | — | — | EP | disclosed |
| EP-0007880-B1 | MEDICINES CONTAINING AS ACTIVE INGREDIENTS COMPOUNDS OF THE BENZENE-SULFONE TYPE; COMPOUNDS OF THIS TYPE AND PROCESS FOR THEIR PREPARATION | CHOAY S.A. (FR) | 1983-07-20 | — | — | EP | disclosed |
| EP-0081425-A1 | Pharmaceutical compositions having normolipemic properties and containing compounds of the n-substituted benzenesulfonamide type | CHOAY S.A. (FR) | 1983-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218632-A1 | CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, SNCA, PINK1 | TDP1 56/4885HTT 71/4885ALDH1A1 2572/4885 |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | TDP1 2567/4885HTT 1537/4885ALDH1A1 4001/4885 |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | TDP1 26/4885HTT 69/4885ALDH1A1 2569/4885 |
| US-20250145578-A1 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | EIF2B3, EIF6, EIF2A | TDP1 1766/4885HTT 4414/4885ALDH1A1 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.